Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LBH domain containing 1 (LBHD1) is a protein-coding gene whose product belongs to a small family of proteins characterized by the LBH (limb-bud and heart) domain. The protein is thought to act as a transcriptional cofactor, lacking a direct DNA-binding domain but capable of modulating transcription via interactions with other transcription factors. LBHD1 has documented roles in embryonic development, particularly in cell differentiation processes related to cartilage and bone (chondrocyte maturation, osteoblast activity), as well as embryonic heart development. Animal models suggest it regulates the activity of key transcription factors such as Runx2, and can indirectly affect pathways like VEGF signaling and angiogenesis in developing tissues. There is currently no evidence that LBHD1 is a conventional therapeutic target (such as a druggable receptor, enzyme, transporter, or immune checkpoint) and no drugs are known to target or modulate its activity. Disease associations include congenital defects in skeletal and cardiac tissues as well as rare genetic variants linked to mitochondrial disorders and hereditary deafness in humans.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LBH domain containing 1 (LBHD1).